Biobanking market was valued at $8.3 billion in 2024 and is projected to reach $20.1 billion by 2035, growing at a CAGR of 8.4% during the forecast period (2025–2035). The global biobanking market growth is driven by increasing demand for biological sample storage and management to support clinical research, precision medicine, and drug discovery activities worldwide. The adoption of biobanking solutions is influenced by technological advancements in automated sample handling systems, digital management platforms, and laboratory information management systems (LIMS), as well as the expanding role of biobanks in genomics, personalized medicine, and multi-omics research. Regulatory frameworks and ethical standards in major markets support standardized biobank operations, including protocols for sample collection, storage, and data governance, which contribute to wider market adoption.
Browse the full report description of “Biobanking Market Size, Share & Trends Analysis Report by Product (Equipment, Consumables, Services, And Software & Informatics) By Sample Type (Blood & Blood Products, Human Tissues, Cell Lines / Primary Cells / Pbmcs / Stem Cells, Nucleic Acids, Biological Fluids, And Microbiome) and by Application (Research & Academic Studies, Drug Discovery & Development, Diagnostics & Biomarker Development, Regenerative Medicine, Precision/Personalized Medicine And Epidemiology, Forensics, And Others) Forecast Period (2025-2035)” of https://www.omrglobal.com/industry-reports/biobanking-market
In the United States, public and private investments in biomedical research infrastructure, precision medicine initiatives, and large-scale genomic programs are supporting the development and utilization of biobank facilities. Compliance with regulatory requirements related to informed consent, biospecimen traceability, and data quality is a key factor for research institutions, pharmaceutical companies, and healthcare organizations, driving investments in automated storage technologies and integrated data management systems. The increasing burden of chronic diseases and the growing volume of clinical trials further contribute to sustained demand for biobanking services.
In Europe, regulatory frameworks and collaborative research funding programs are supporting the establishment of national and regional biobanks, enabling cross-institutional data sharing and large-scale population studies. Countries such as the United Kingdom, Germany, and France are focusing on the development of disease-specific and population-based biobanks to strengthen translational research and precision medicine strategies. The adoption of digital tools for sample tracking, remote data access, and cloud-based management platforms is also improving operational efficiency and facilitating broader integration of biobanking across healthcare and research ecosystems.
Key Innovators Driving the Global Biobanking Market
The key players in the global biobanking market include Avantor Inc., Hamilton Company, Merck KGaA, QIAGEN, and Thermo Fisher Scientific Inc., among others. These companies are developing technologies focused on biospecimen collection, automated sample handling, ultra-low temperature storage, digital sample tracking, and laboratory information management systems (LIMS), which support clinical research, genomics, and pharmaceutical development.
Market Coverage
Key questions addressed by the report.
Biobanking market Report Segment
By Product
By Sample Type
By Application
Biobanking market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/biobanking-market